Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations
in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1).
These mutations result in the body's overproduction of interleukin-1 (IL-1), a protein that
stimulates the inflammatory process. IL-1 Trap (rilonacept) was designed to bind to the
interleukin-1 cytokine and prevent it from binding to its receptors in the body.